• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance

- Voluntary recall and notice of corrective action issued after discovering certain blister card packages distributed in the U.S. do not meet U.S. child-resistant packaging requirements

- Certain lots of Risperidone ODT, Donepezil ODT, Naratriptan, Ondansetron ODT, Ondansetron tablets, and Zofran ODT® (ondansetron) in blister card packages are recalled, as well as certain lots of products in Hospital Unit Dose blister packaging that may have reached consumers, including Azithromycin, Haloperidol, Imipramine, ISDN (isosorbide dinitrate), Perphenazine and Entresto® (sacubitril/valsartan)

- Products dispensed in bottles are NOT impacted by this recall

- There are no quality or safety issues with the medicines for their intended use

- Patients should immediately secure impacted blister card packages and their contents to keep out of the sight and reach of children

- Patients should continue to use the medicine as prescribed and call 1-888-NOW NOVA (1-888-669-6682) for important information on corrective actions


News provided by

Novartis Pharmaceuticals Corporation

Jul 06, 2018, 16:15 ET

Share this article

Share this article


PRINCETON, N.J., July 6, 2018 /PRNewswire/ -- Sandoz Inc. (Sandoz) and its affiliate, Novartis Pharmaceuticals Corporation (Novartis), today announced a voluntary recall and corrective action notice for certain lots of product distributed in the U.S. in pre-packaged blister card packages (blister packs) after learning that these blister packs do not meet federal standards for child-resistant packaging, posing a risk of harm if the tablets are swallowed by children.

At Sandoz and Novartis, we take our responsibility for consumer safety very seriously. As soon as we became aware of the issue, we immediately notified the U.S. Consumer Product Safety Commission (CPSC) and Food and Drug Administration (FDA) that the blister packs at issue are not compliant for consumer home use. As a result, we are voluntarily recalling and implementing corrective action for these selected blister packs.

This action is only necessary because the blister packs are not child-resistant. There are no quality or safety issues with the medicines for their intended use. Patients should continue taking their medicine as directed by their physician, secure the affected blister packs so that they are out of the sight and reach of children, and contact Novartis at 1-888-NOW NOVA or 1-888-669-6682 for instructions. Products in bottles are NOT impacted by this recall. 

Sandoz Products
The products affected by the recall and corrective action notice include production lots of the following medicines in blister packs that have been distributed by Sandoz in the U.S. to date:

Azithromycin: 250mg tablets in 50 count hospital unit dose blister packages. The only affected National Drug Code (NDC) number for cartons is: #0781-5776-69. The only affected NDC number for blister pack is: #0781-5776-06. This recall does NOT include Azithromycin 250mg 6 tablet or 500mg 3 tablet blister packs or any product dispensed by pharmacists in bottles.

Donepezil ODT: 5mg and 10mg in 30 count unit dose blister packs. The affected NDC numbers on cartons are: #0781-5276-64 and #0781-5277-64. The affected NDC numbers for blister packs are: #0781-5276-06 and #0781-5277-06.

Haloperidol: 0.5mg, 1mg, 2mg, 5mg and 10mg in 100 count hospital unit dose blister packages. The affected NDC numbers are: #0781-1391-13, #0781-1392-13, #0781-1393-13, #0781-1396-13 and #0781-1397-13. This recall does NOT include any product dispensed by pharmacists in bottles.

Imipramine: 25mg and 50mg in 100 count hospital unit dose blister packages. The affected NDC numbers are #0781-1764-13 and #0781-1766-13. This recall does NOT include any product dispensed by pharmacists in bottles. 

ISDN (Isosorbide dinitrate): 10mg and 20mg in 100 count hospital unit dose blister packages. The affected NDC numbers are #0781-1556-13 and #0781-1695-13. This recall does NOT include any product dispensed by pharmacists in bottles.

Naratriptan: 2.5mg in 9 count unit dose blister packs. The affected NDC number for carton is: #0781-5527-37. The affected NDC number for blister pack is: #0781-5527-06.

Ondansetron ODT: 4mg and 8mg Orally Disintegrating Tablets (ODT) in blister packs. The affected NDC numbers for cartons are: #0781-5238-64, #0781-5239-80 and #0781-5239-64. The affected NDC numbers for blister packs are: #0781-5238-06 and #0781-5239-06.

Ondansetron:  8mg tablets in blister packs of 3 tablets. The only affected NDC number is #0781-1681-33.  This recall does NOT include Ondansetron 4mg tablets in unit dose blister packs of 3 tablets or Ondansetron tablets dispensed by pharmacists in bottles.

Perphenazine: 2mg, 4mg and 8mg in 100 count hospital unit dose blister packages. The affected NDC numbers are #0781-1046-13, #0781-1047-13 and #0781-1048-13. This recall does NOT include any product dispensed by pharmacists in bottles. 

Risperidone ODT: 0.5mg, 1mg, 2mg, 3mg and 4mg Orally Disintegrating Tablets (ODT) in 28 count blister packs. The affected NDC numbers for cartons are: #0781-5310-08, #0781-5311-08, #0781-5312-08, #0781-5313-08, and #0781-5314-08. The affected NDC numbers for blister packs are: #0781-5310-06, #0781-5311-06, #0781-5312-06, #0781-5313-06 and #0781-5314-06.

Consumers or pharmacies who have impacted blister packs with these NDC numbers in their homes or pharmacies should contact Novartis at 1-888-NOW NOVA or 1-888-669-6682 for important instructions on corrective actions. A complete list of the affected lot numbers with expiry dates and package photos is available at   

https://www.us.sandoz.com/patients-customers/product-safety-notices

Novartis Products
The products affected by the recall and corrective action notice include production lots of the following medicines in blister packs that have been distributed by Novartis in the U.S. to date:

Entresto® (sacubitril/valsartan) tablets: 24mg/26mg, 49mg/51mg and 97mg/103mg in 100 count tablet hospital unit dose blister packages. The affected NDC numbers for cartons are #0078-0659-35, #0078-0777-35 and #0078-0696-35. The affected NDC numbers for blister packs are #0078-0659-61, #0078-0777-61, and #0078-0696-61. This recall and corrective action notice does NOT include tablets dispensed by pharmacists in bottles.

Zofran® ODT (ondansetron): 4mg and 8mg Orally Disintegrating Tablets (ODT) in blister packs. The affected NDC numbers for cartons are: #0078-0679-19 and #0078-0680-19. The affected NDC numbers for blister packs are: #0078-0679-61 and #0078-0680-61.

A complete list of the affected lot numbers with expiry dates and package photos is available at

https://www.pharma.us.novartis.com/recall-zofran-and-entresto-packages

Consumers or pharmacies who have impacted blister packs with these NDC numbers in their homes or pharmacies should contact Novartis at 1-888-NOW NOVA or 1-888-669-6682 for important instructions on corrective actions. For more information on Novartis products, please find details on our website: https://www.pharma.us.novartis.com/. 

About Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.

Follow our blog at www.sandoz.com/makingaccesshappen.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 124,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.

Novartis Media Relations
Central media line: +41 61 324 2200
Email: [email protected]



Eric Althoff

Novartis Global Media Relations

+41 61 324 7999 (direct)

+41 79 593 4202 (mobile)

[email protected]

Chris Lewis

Sandoz Global Communications

+49 8024 476 1906 (direct)

[email protected]


Leslie Pott

Sandoz US Communications

+1 609 627 5287

[email protected]



Novartis Investor Relations

Central investor relations line: +41 61 324 7944      
Email: [email protected]





Central


North America


Samir Shah

+41 61 324 7944

Richard Pulik

+1 212 830 2448

Pierre-Michel Bringer

+41 61 324 1065

Cory Twining

+1 212 830 2407

Thomas Hungerbuehler

+41 61 324 8425



Isabella Zinck

+41 61 324 7188



SOURCE Novartis Pharmaceuticals Corporation

Related Links

http://www.novartis.com

Modal title

Also from this source

Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5


Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Pharmaceuticals
  • Product Recalls

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.